Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

1.

[Paricalcitol: an ally against proteinuria in diabetic patients?].

Galassi A.

G Ital Nefrol. 2011 Mar-Apr;28(2):137. Italian. No abstract available.

PMID:
21488023
[PubMed - indexed for MEDLINE]
2.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
[PubMed - indexed for MEDLINE]
3.

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D.

Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.

PMID:
21055801
[PubMed - indexed for MEDLINE]
4.

Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.

Nuijten M, Andress DL, Marx SE, Sterz R.

Curr Med Res Opin. 2009 May;25(5):1221-34. doi: 10.1185/03007990902844097 .

PMID:
19335321
[PubMed - indexed for MEDLINE]
5.

Does paricalcitol reduce proteinuria in patients with chronic kidney disease?

Nishizawa Y, Shoji T.

Nat Clin Pract Nephrol. 2006 Jul;2(7):352-3. No abstract available.

PMID:
16932459
[PubMed - indexed for MEDLINE]
6.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
[PubMed - indexed for MEDLINE]
7.

VDRAs versus calcimimetics: better safe than sorry?

Cozzolino M, Brancaccio D.

Kidney Int. 2008 Oct;74(7):966; author reply 966-7. doi: 10.1038/ki.2008.363. No abstract available.

PMID:
18794826
[PubMed - indexed for MEDLINE]
8.

Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells.

Sochorová K, Budinský V, Rozková D, Tobiasová Z, Dusilová-Sulková S, Spísek R, Bartůnková J.

Clin Immunol. 2009 Oct;133(1):69-77. doi: 10.1016/j.clim.2009.06.011. Epub 2009 Aug 5.

PMID:
19660988
[PubMed - indexed for MEDLINE]
9.

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy.

Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R.

N Engl J Med. 2003 Jul 31;349(5):446-56.

PMID:
12890843
[PubMed - indexed for MEDLINE]
Free Article
10.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50.

PMID:
11689387
[PubMed - indexed for MEDLINE]
11.

Antiproteinuric effect of oral paricalcitol in chronic kidney disease.

Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D.

Kidney Int. 2005 Dec;68(6):2823-8.

PMID:
16316359
[PubMed - indexed for MEDLINE]
12.

The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.

Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M.

Kidney Int. 2008 Feb;73(3):300-7. Epub 2007 Nov 14.

PMID:
18004298
[PubMed - indexed for MEDLINE]
13.

The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics.

Lambers Heerspink HJ, Agarwal R, Coyne DW, Parving HH, Ritz E, Remuzzi G, Audhya P, Amdahl MJ, Andress DL, de Zeeuw D.

Am J Nephrol. 2009;30(3):280-6. doi: 10.1159/000225903. Epub 2009 Jun 15.

PMID:
19521070
[PubMed - indexed for MEDLINE]
14.

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings.

Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM.

Nephrol Dial Transplant. 2004 May;19(5):1174-81. Epub 2004 Mar 5.

PMID:
15004264
[PubMed - indexed for MEDLINE]
Free Article
15.

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

Sprague SM, Lerma E, McCormmick D, Abraham M, Batlle D.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S51-6.

PMID:
11689388
[PubMed - indexed for MEDLINE]
16.

Comparative cost-benefit analyses of paricalcitol and calcitriol in stage 4 chronic kidney disease from the perspective of a health plan.

Gal-Moscovici A, Sprague SM.

Clin Drug Investig. 2007;27(2):105-13.

PMID:
17217315
[PubMed - indexed for MEDLINE]
17.

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

Ratnam S, Kaw D, Rao P.

N Engl J Med. 2003 Nov 13;349(20):1971-2; author reply 1971-2. No abstract available.

PMID:
14626257
[PubMed - indexed for MEDLINE]
18.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
[PubMed - indexed for MEDLINE]
19.

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

Colussi G.

N Engl J Med. 2003 Nov 13;349(20):1971-2; author reply 1971-2. No abstract available.

PMID:
14614175
[PubMed - indexed for MEDLINE]
Free Article
20.

Paricalcitol, calcitriol, and survival of patients undergoing hemodialysis.

Kida Y.

N Engl J Med. 2003 Nov 13;349(20):1971-2; author reply 1971-2. No abstract available.

PMID:
14626256
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk